



ÅRSREGNSKAPET FOR REGNSKAPSÅRET 2025 - GENERELL INFORMASJON

Enheten

Organisasjonsnummer: 915 642 888
Organisasjonsform: Aksjeselskap
Foretaksnavn: ASCENSIA DIABETES CARE NORWAY AS
Forretningsadresse: Strandveien 50
1366 LYSAKER

Regnskapsår

Årsregnskapets periode: 01.04.2024 - 31.03.2025

Konsern

Morselskap i konsern: Nei

Regnskapsregler

Regler for små foretak benyttet: Nei
Benyttet ved utarbeidelsen av årsregnskapet til selskapet: Regnskapslovens alminnelige regler

Årsregnskapet fastsatt av kompetent organ

Bekreftet av representant for selskapet: Helland Iveta
Dato for fastsettelse av årsregnskapet: 30.09.2025

Grunnlag for avgivelse

År 2025: Årsregnskapet er elektronisk innlevert
År 2024: Tall er hentet fra elektronisk innlevert årsregnskap fra 2025

Det er ikke krav til at årsregnskapet m.v. som sendes til Regnskapsregisteret er undertegnet. Kontrollen på at dette er utført ligger hos revisor/enhetens øverste organ. Sikkerheten ivaretas ved at innsender har rolle/rettighet for innsending av årsregnskapet via Altinn, og ved at det bekreftes at årsregnskapet er fastsatt av kompetent organ.

Brønnøysundregistrene, 24.10.2025



Resultatregnskap

Beløp i: NOK	Note	2025	2024
RESULTATREGNSKAP			
Inntekter			
Salgsinntekt	2, 3	116 198 809	110 706 479
Sum inntekter		116 198 809	110 706 479
Kostnader			
Varekostnad	3	58 646 928	61 436 340
Lønnskostnad	4, 5	29 910 509	24 190 276
Avskrivning	8	51 780	51 779
Annen driftskostnad	3, 4	19 246 922	18 357 052
Sum kostnader		107 856 139	104 035 447
Driftsresultat		8 342 670	6 671 032
Finansinntekter og finanskostnader			
Annen finansinntekt	6	42 155	72 237
Sum finansinntekter		42 155	72 237
Annen finanskostnad	6	22 046	45 365
Sum finanskostnader		22 046	45 365
Netto finans		20 109	26 872
Ordinært resultat før skattekostnad		8 362 779	6 697 904
Skattekostnad på ordinært resultat	7	1 841 847	1 474 032
Ordinært resultat etter skattekostnad		6 520 932	5 223 872
Årsresultat		6 520 932	5 223 872
Overføringer og disponeringer			
Ordinært utbytte	11	8 326 429	
Overføringer annen egenkapital	11	-1 805 497	5 223 872
Sum overføringer og disponeringer		6 520 932	5 223 872



Balanse

Beløp i: NOK	Note	2025	2024
BALANSE - EIENDELER			
Anleggsmidler			
Immaterielle eiendeler			
Utsatt skattefordel	7	1 184 627	534 595
Sum immaterielle eiendeler		1 184 627	534 595
Varige driftsmidler			
Driftsløsøre, inventar, verktøy, kontormaskiner ol	8	64 724	116 504
Sum varige driftsmidler		64 724	116 504
Finansielle anleggsmidler			
Andre fordringer	5, 5	0	224 482
Sum finansielle anleggsmidler		0	224 482
Sum anleggsmidler		1 249 351	875 581
Omløpsmidler			
Varer			
Fordringer			
Kundefordringer	9	23 286 133	19 555 090
Andre fordringer		800 257	4 178 185
Sum fordringer		24 086 390	23 733 275
Bankinnskudd, kontanter og lignende			
Sum bankinnskudd, kontanter og lignende	10	30 061 482	27 087 641
Sum omløpsmidler		54 147 872	50 820 916
SUM EIENDELER		55 397 223	51 696 497

BALANSE - EGENKAPITAL OG GJELD

Egenkapital

Innskutt egenkapital



Balanse

Beløp i: NOK	Note	2025	2024
Aksjekapital	11, 12	103 200	103 200
Overkurs	11	14 146 330	14 146 330
Sum innskutt egenkapital		14 249 530	14 249 530
Opptjent egenkapital			
Annen egenkapital	11	0	5 083 471
Sum opptjent egenkapital		0	5 083 471
Sum egenkapital		14 249 530	19 333 001
Gjeld			
Langsiktig gjeld			
Pensjonsforpliktelser	5	3 232 622	
Sum avsetninger for forpliktelser		3 232 622	0
Annen langsiktig gjeld			
Øvrig langsiktig gjeld		1 166 675	634 207
Sum annen langsiktig gjeld		1 166 675	634 207
Sum langsiktig gjeld		4 399 297	634 207
Kortsiktig gjeld			
Leverandørgjeld	9	11 644 063	15 502 918
Betalbar skatt	7	2 308 202	1 488 450
Skyldige offentlige avgifter	10	5 492 789	7 216 605
Utbytte	9, 11	8 326 429	
Annen kortsiktig gjeld	9	8 976 913	7 521 317
Sum kortsiktig gjeld		36 748 396	31 729 290
Sum gjeld		41 147 693	32 363 497
SUM EGENKAPITAL OG GJELD		55 397 223	51 696 498



Brønnøysundregistrene

ÅRSREGNSKAP FOR REGNSKAPSÅRET 2025 - GENERELL INFORMASJON

Journalnummer: 2025 760794

Enheten

Organisasjonsnummer: 915 642 888
Organisasjonsform: Aksjeselskap
Foretaksnavn: ASCENSIA DIABETES CARE NORWAY AS
Forretningsadresse: Strandveien 50
1366 LYSAKER

Regnskapsår

Årsregnskapets periode: 01.04.2024 - 31.03.2025

Konsern

Morselskap i konsern: Nei

Regnskapsregler

Regler for små foretak benyttet: Nei
Benyttet ved utarbeidelsen av
årsregnskapet til selskapet: Regnskapslovens alminnelige regler

Årsregnskapet fastsatt av kompetent organ

Bekreftet av representant for selskapet: Helland Iveta
Dato for fastsettelse av årsregnskapet: 30.09.2025

Grunnlag for avgivelse

År 2025: Årsregnskap er elektronisk innlevert.
År 2024: Tall er hentet fra elektronisk innlevert årsregnskap fra 2025.

Det er ikke krav til at årsregnskapet m.v. som sendes til Regnskapsregisteret er undertegnet. Kontrollen på at dette er utført ligger hos revisor/enhetens øverste organ. Sikkerheten ivaretas ved at innsender har rolle/rettighet for innsending av årsregnskapet via Altinn, og ved at det bekreftes at årsregnskapet er fastsatt av kompetent organ.

Brønnøysundregistrene, 23.10.2025



Organisasjonsnr: 915 642 888
ASCENSIA DIABETES CARE NORWAY AS

RESULTATREGNSKAP

Beløp i: NOK	Note	2025	2024
RESULTATREGNSKAP			
Inntekter			
Salgsinntekt	2, 3	116 198 809	110 706 479
Sum inntekter		116 198 809	110 706 479
Kostnader			
Varekostnad	3	58 646 928	61 436 340
Lønnskostnad	4, 5	29 910 509	24 190 276
Avskrivning	8	51 780	51 779
Annen driftskostnad	3, 4	19 246 922	18 357 052
Sum kostnader		107 856 139	104 035 447
Driftsresultat		8 342 670	6 671 032
Finansinntekter og finanskostnader			
Annen finansinntekt	6	42 155	72 237
Sum finansinntekter		42 155	72 237
Annen finanskostnad	6	22 046	45 365
Sum finanskostnader		22 046	45 365
Netto finans		20 109	26 872
Ordinært resultat før skattekostnad			
Skattekostnad på ordinært resultat	7	1 841 847	1 474 032
Ordinært resultat etter skattekostnad		6 520 932	5 223 872
Årsresultat		6 520 932	5 223 872
Overføringer og disponeringer			
Ordinært utbytte	11	8 326 429	
Overføringer annen egenkapital	11	-1 805 497	5 223 872
Sum overføringer og disponeringer		6 520 932	5 223 872



Organisasjonsnr: 915 642 888
ASCENSIA DIABETES CARE NORWAY AS

BALANSE

Beløp i: NOK	Note	2025	2024
BALANSE - EIENDELER			
Anleggsmidler			
Immaterielle eiendeler			
Utsatt skattefordel	7	1 184 627	534 595
Sum immaterielle eiendeler		1 184 627	534 595
Varige driftsmidler			
Driftsløsøre, inventar, verktøy, kontormaskiner ol	8	64 724	116 504
Sum varige driftsmidler		64 724	116 504
Finansielle anleggsmidler			
Andre fordringer	5, 5	0	224 482
Sum finansielle anleggsmidler		0	224 482
Sum anleggsmidler		1 249 351	875 581
Omløpsmidler			
Varer			
Fordringer			
Kundefordringer	9	23 286 133	19 555 090
Andre fordringer		800 257	4 178 185
Sum fordringer		24 086 390	23 733 275
Bankinnskudd, kontanter og lignende			
Sum bankinnskudd, kontanter og lignende	10	30 061 482	27 087 641
Sum omløpsmidler		54 147 872	50 820 916
SUM EIENDELER		55 397 223	51 696 497
BALANSE - EGENKAPITAL OG GJELD			
Egenkapital			
Innskutt egenkapital			
Aksjekapital	11, 12	103 200	103 200
Overkurs	11	14 146 330	14 146 330
Sum innskutt egenkapital		14 249 530	14 249 530
Opptjent egenkapital			
Annen egenkapital	11	0	5 083 471
Sum opptjent egenkapital		0	5 083 471



Sum egenkapital		14 249 530	19 333 001
Gjeld			
Langsiktig gjeld			
Pensjonsforpliktelser	5	3 232 622	
Sum avsetninger for forpliktelser		3 232 622	0
Annen langsiktig gjeld			
Øvrig langsiktig gjeld		1 166 675	634 207
Sum annen langsiktig gjeld		1 166 675	634 207
Sum langsiktig gjeld		4 399 297	634 207
Kortsiktig gjeld			
Leverandørgjeld	9	11 644 063	15 502 918
Betalbar skatt	7	2 308 202	1 488 450
Skyldige offentlige avgifter	10	5 492 789	7 216 605
Utbytte	9, 11	8 326 429	
Annen kortsiktig gjeld	9	8 976 913	7 521 317
Sum kortsiktig gjeld		36 748 396	31 729 290
Sum gjeld		41 147 693	32 363 497
SUM EGENKAPITAL OG GJELD		55 397 223	51 696 498



Organisasjonsnr: 915 642 888
ASCENSIA DIABETES CARE NORWAY AS

NOTEOPPLYSNINGER - SELSKAP - alle poster oppgitt i hele tall

Note
12

Antall aksjer og aksjeeiere

<u>Aksjeklasse</u>	<u>Ant. aksjer</u>	<u>Pålydende</u>	<u>Bokført verdi</u>
Ordinary shares	2400.00	43.00	103200.00
<u>Aksjeeiere - fritekst</u>	<u>Antall</u>	<u>Eierandel</u>	<u>Aksjeklasse</u>
Ascensia Diabetes Care Holdings AG	2400.00	100.00%	Ordinary shares
<u>Sum</u>	<u>Sum antall</u>	<u>Sum eierandel</u>	
	2400.00	100.00%	

The entity is part of the consolidated accounts for Ascensia Diabetes Care Holdings AG, whose address is: Ascensia Diabetes Care Holdings AG, Merian-Str. 90, 4052 Basel, Switzerland. The consolidated accounts can be obtained from:
<https://holdings.panasonic/global/corporate/investors.html>

Note
4

Lønn og ytelser

<u>Lønn</u>	<u>Årets</u>	<u>Fjorårets</u>
	20505127.00	17833874.00
<u>Arbeidsgiveravgift</u>	<u>Årets</u>	<u>Fjorårets</u>
	4049794.00	3429569.00
<u>Pensjonskostnader</u>	<u>Årets</u>	<u>Fjorårets</u>
	4238384.00	1211217.00
<u>Andre ytelser</u>	<u>Årets</u>	<u>Fjorårets</u>
	1117204.00	1715616.00
<u>Sum lønnskostnader</u>	<u>Årets</u>	<u>Fjorårets</u>
	29910509.00	24190276.00

The entity is required to have an occupational pension scheme in accordance with the Act on Mandatory Occupational Pensions. The entity's pension schemes satisfy the requirements of this Act.



Any remuneration has not paid to the general manager or the board of directors for acting as a member of board during the year. There are no loans/securities issued to the general manager or board of directors.

Note

Ytelser til revisjon

<u>Revisjon</u>	<u>Årets</u>	<u>Fjorårets</u>
	406599.00	295619.00
<u>Sum godtgjørelse til revisor</u>	<u>Årets</u>	<u>Fjorårets</u>
	406599.00	295619.00

Note

Antall årsverk i regnskapsåret

Virksomheten har hatt følgende antall årsverk:
0.00

<u>Omløpsmidler</u>	<u>Startdato</u>	<u>Sluttdato</u>	<u>Endring</u>
<u>Skattemessig fremf.undersk.</u>	<u>Startdato</u>	<u>Sluttdato</u>	<u>Endring</u>
<u>Kortsiktig gjeld</u>	<u>Startdato</u>	<u>Sluttdato</u>	<u>Endring</u>



Skattedirektoratet

Saksbehandler Rune Tystad	Deres dato 03.10.2017	Vår dato 24.10.2017
Telefon 97759464	Deres referanse Lars Helland	Vår referanse 2017757183

ERNST & YOUNG AS
Postboks 8015
4313 SANDNES

Tillatelse til å utarbeide årsregnskap og årsberetning på engelsk språk for Ascensia Diabetes Care Norway AS, org.nr. 915 642 888

Vi viser til deres brev av 3. oktober 2017 der dere søker om dispensasjon fra kravet til å utarbeide årsregnskap og årsberetning på norsk språk for Ascensia Diabetes Care Norway AS.

Skattedirektoratet gir på bakgrunn av en konkret helhetsvurdering Ascensia Diabetes Care Norway AS dispensasjon fra kravet til å utarbeide årsregnskap og årsberetning på norsk språk, jf. regnskapsloven § 3-4 tredje ledd. Dispensasjonen gjelder så lenge opplysningene som vedtaket baserer seg på ikke endres vesentlig.

Kopi av dette brevet må sendes Regnskapsregisteret i Brønnøysund sammen med årsregnskapet. Det påligger den regnskapspliktige å dokumentere ved dette brev at tillatelsen er gitt.

Bakgrunn

Fra deres søknad gjengis:

Ascensia Diabetes Care Norway AS (org.nr. 915 642 888) er et norsk aksjeselskap og driver virksomhet knyttet til produksjon, markedsføring og salg av farmasøytiske produkter innen legemiddel- og helseindustrien.

Selskapets arbeidsspråk er engelsk da selskapet er eid av et utenlandsk selskap. Styremedlemmer og kontaktperson i selskapet kommuniserer med morselskapet i utlandet noe som gjør at regnskapet bør utarbeides på engelsk.

Både arbeidsspråket til selskapet og bransjespråket der selskapet opererer er engelsk, derfor fremstår kravet i regnskapsloven § 3-4 om utarbeidelse av årsregnskap og årsberetning på norsk som lite anvendelig for selskapet. I tillegg til at det er ressurskrevende, fører av og til tvil om oversettelse og uoverensstemmelser mellom engelsk og norsk versjon til unødvendige misforståelser.

Etttersom selskapets arbeidsspråk er engelsk vil alle ansatte forstå regnskapet og årsberetningen selv om disse dokumentene i fremtiden blir utarbeidet i sin endelige form på engelsk. Det samme vil være tilfelle for selskapets kunder og kreditorer. Etttersom engelsk også er bransjespråket innen sektorene de opererer i, kan vi heller ikke se at andre, mer tilfeldige regnskapsbrukere skulle ha noe behov for at regnskapet utarbeides på norsk. Selskapet mener derfor at alle brukere av regnskapet i sum vil være tjent med at regnskapet kun utarbeides på engelsk.

Postadresse
Postboks 9200 Grønland
0134 Oslo

Besøksadresse: Sentralbord
Se www.skatteetaten.no 800 80 000
Org.nr: 996250318 Telefaks
E-post: skatteetaten.no/sendepost 22 17 06 60



Skattedirektoratets vurdering

Etter regnskapsloven § 3-4 tredje ledd skal "årsregnskapet og årsberetningen ... være på norsk. Departementet kan ved ... enkeltvedtak bestemme at årsregnskapet og/eller årsberetningen kan være på et annet språk."

I Ot. prp. nr. 42 (1997-1998) Om lov om årsregnskap m.v., er det uttalt følgende om regnskapslovens formål, jf. pkt. 1.1:

"Regjeringen har som siktemål at regnskapsloven skal bidra til informative regnskaper for ulike grupper av regnskapsbrukere. Regnskapsbrukerne er dels investorer og kreditorer som tilfører kapital til foretakene, og dels andre grupper som har interesse av å vite hvordan foretaket drives, f.eks. de ansatte og lokalsamfunnet. Informasjonen til kapitalmarkedet skal gi grunnlag for riktig prising av finansielle objekter. Riktig prisdannelse på aksjer er en forutsetning for at ressursbruken i samfunnsøkonomien skal bli best mulig. Gode regnskaper vil også gjøre det vanskeligere for markedsdeltakere å ta ut spekulasjonsgevinster med basis i skjevt fordelt informasjon."

Det fremgår således at et av hovedformålene med regnskapsloven er å bidra til "informative regnskaper for ulike grupper av regnskapsbrukere". Regnskapsbrukere vil omfatte, jf. uttalelsen i proposisjonen, blant andre investorer, kreditorer, ansatte og lokalsamfunnet. Det er etter Skattedirektoratets vurdering derfor avgjørende ved vurdering av om dispensasjon fra kravet til å utarbeide årsregnskap og/eller årsberetning på norsk kan gis, at det ikke foreligger mulige brukere av regnskapsinformasjon som blir vesentlig berørt negativt ved en eventuell dispensasjon.

Det er særlig hensynet til brukerne av regnskapsinformasjon som skal vurderes ved en dispensasjonssøknad. I denne vurderingen har Skattedirektoratet lagt vekt på at selskapet er eid av et utenlandsk selskap og at eierkretsen derfor er begrenset. Videre er det vektlagt at selskapets arbeidsspråk er engelsk og at bransjespråket der selskapet opererer er engelsk.

Vennligst oppgi vår referanse ved henvendelser i saken.

Med hilsen

Torstein Kinden Helleland
seniorrådgiver
Rettsavdelingen, foretaksskatt
Skattedirektoratet

Rune Tystad

Dokumentet er elektronisk godkjent og har derfor ikke håndskrevne signaturer



KPMG AS
Sørkedalsveien 6
P.O. Box 7000 Majorstuen
N-0306 Oslo

Telephone +47 45 40 40 63
Internet www.kpmg.no
Enterprise 935 174 627 MVA

To the General Meeting of Ascensia Diabetes Care Norway AS

Independent Auditor's Report

Opinion

We have audited the financial statements of Ascensia Diabetes Care Norway AS (the Company), which comprise the balance sheet as at 31 March 2025, the income statement and cash flow statement for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion

- the financial statements comply with applicable statutory requirements, and
- the financial statements give a true and fair view of the financial position of the Company as at 31 March 2025, and its financial performance and its cash flows for the year then ended in accordance with the Norwegian Accounting Act and accounting standards and practices generally accepted in Norway.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company as required by relevant laws and regulations in Norway and the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (including International Independence Standards) (IESBA Code), and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Information

The Board of Directors (management) is responsible for the information in the Board of Directors' report. The other information comprises information in the annual report, but does not include the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the information in the Board of Directors' report.

In connection with our audit of the financial statements, our responsibility is to read the Board of Directors' report. The purpose is to consider if there is material inconsistency between the Board of Directors' report and the financial statements or our knowledge obtained in the audit, or whether the Board of Directors' report otherwise appears to be materially misstated. We are required to report if there is a material misstatement in the Board of Directors' report. We have nothing to report in this

Offices in:

© KPMG AS, a Norwegian limited liability company and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.

Statsautoriserte revisorer - medlemmer av Den norske Revisorforening

Oslo	Elverum	Mo i Rana	Tromsø
Alta	Finnsnes	Molde	Trondheim
Arendal	Hamar	Sandefjord	Tynset
Bergen	Haugesund	Slavanger	Ulsteinvik
Bode	Knarvik	Stord	Alesund
Drammen	Kristiansand	Straume	

Penneo Dokumentnøkkel: H48TL-99R01-DMNKD-BL14L-FQM9C-GBR3A



regard.

Based on our knowledge obtained in the audit, it is our opinion that the Board of Directors' report

- is consistent with the financial statements and
- contains the information required by applicable statutory requirements.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Norwegian Accounting Act and accounting standards and practices generally accepted in Norway, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern. The financial statements use the going concern basis of accounting insofar as it is not likely that the enterprise will cease operations.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error. We design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves a true and fair view.



We communicate with the Board of Directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Oslo, 30th of September 2025

KPMG AS

Gunnar Sotnakk
State Authorised Public Accountant
(This document is signed electronically)

Penneo Dokumentnøkkel: I481L-99R01-DMNKD-BL14L-FQM9C-GBR3A



PENNEO

Signaturene i dette dokumentet er juridisk bindende. Dokument signert med "Penneo™ - sikker digital signatur". De signerende parter sin identitet er registrert, og er listet nedenfor.

"Med min signatur bekrefter jeg alle datoer og innholdet i dette dokument."

Gunnar Sotnakk

Statsautorisert revisor

På vegne av: KPMG AS

Serienummer: bankid.no no_bankid:9578-5993-4-2025853

IP: 80.232.xxx.xxx

2025-09-30 15:25:17 UTC



QES



Dette dokumentet er signert digitalt via [Penneo.com](https://penneo.com). De signerte dataene er validert ved hjelp av den matematiske hashverdien av det originale dokumentet. All kryptografisk bevisføring er innebygd i denne PDF-en for fremtidig validering.

Dette dokumentet er forseglet med et kvalifisert elektronisk segl. For mer informasjon om Penneos kvalifiserte tillitstjenester, se <https://eud.penneo.com>.

Slik kan du bekrefte at dokumentet er originalt

Når du åpner dokumentet i Adobe Reader, kan du se at det er sertifisert av **Penneo A/S**. Dette beviser at innholdet i dokumentet ikke har blitt endret siden tidspunktet for signeringen. Bevis for de individuelle signatørens digitale signaturer er vedlagt dokumentet.

Du kan bekrefte de kryptografiske bevisene ved hjelp av Penneos validator, <https://penneo.com/validator>, eller andre valideringsverktøy for digitale signaturer.



ASCENSIA DIABETES CARE NORWAY AS

ANNUAL REPORT 2024

The business

Ascensia Diabetes Care Norway AS (ADC Norway AS) was established in 2015, and the business activities started at the beginning of 2016 through the acquisition of Bayer Diabetes Care by Panasonic Healthcare Holdings.

The company is a wholly owned subsidiary of Ascensia Diabetes Care Holdings AG, corporate identity number CHE 427.105.881, registered office in Basel, Switzerland, which is part of Ascensia Diabetes Care Group. The consolidated financial statements of the foreign parent company can be obtained from PHC Holdings Corporation, 15F DAI-ICHI LIFE HIBIYA FIRST 1-13-2 Yurakucho, Chiyoda-ku, Tokyo100-8403, Japan.
<https://www.phchd.com/global/ir/result>

The company provides solutions for assisting and supporting people with diabetes, enabling them to live as safe and secure a life as possible. The business is located and run out of Lysaker in Bærum.

ADC Norway AS is responsible for all sales and marketing activities aimed at end users who have diabetes or are associated with people with diabetes, and healthcare professionals. Ascensia has more than 80 years of experience with helping people handle their diabetes.

Business Model

Ascensia Diabetes Care Norway AS is a wholly owned indirect subsidiary of PHC Holdings Corporation, within the Ascensia Diabetes Care Group. During the financial year the Company's trading model remained consistent, predominantly acting as a sales and marketing entity for the Ascensia Group in Norway, buying finished good product from the Company's parent company, Ascensia Diabetes Care Holdings AG, for resale in Norway.

Financial performance

Management considers the Company's financial performance in the year satisfactory. The market share grew slightly and remained at a high level, and the company is well-equipped



for the future. The fact that the company is operating in a therapeutic area of chronic ill patients provides a strong level of stability and predictability to the business and performance. Moreover, the product offering is fully reimbursed by the National health care fund (HELFO) which means that the company is less subjected to sudden changes in commercial terms. The major reasons for the levelled sales revenue in 2024/2025 is a declining market for Blood Glucose Self testing compensated by a reduction of parallel import from other EU countries.

The revenues increased slightly from NOK 110 706 479 in 2023/2024 to NOK 116 198 809 in 2024/2025. The income statement for 2024/2025 shows a net profit of NOK 6 520 932 against a net profit of NOK 5 223 872 last year. The balance sheet at 31 March 2025 shows equity of NOK 14 249 530 and a total balance of NOK 55 397 223.

Dividend NOK 8 326 429

Transfers other equity NOK – 1 805 497

Sum predisposed NOK 6 520 932

Net cash flow from operating activities was NOK 2 973 841 and the operating result constituted NOK 8 342 670. The operating result is significantly higher in comparison to previous fiscal year 2023/2024, and there is small decrease in the net cash flow from operating activities.

The liquidity reserve as of 31.03.2025 amounted to NOK 30 061 90482. Liquidity is considered satisfactory. There is a NOK 5 million revolving facility in place between ADC Holdings AG and ADC Norway AS, which can be used in case of liquidity necessity. The low risk distribution model between ADC Holdings and ADC Norway AS has been adapted to avoid any local liquidity risk.

Total assets at 31.03.2025 amounted NOK 55 397 223, compared NOK 51 696 498 last year. The equity ratio was 26 % of 31.03.2025, compared to 37 % the year before. The gross margin was 49 %, compared to 45 % the year before.

Research and development activities

The company does not have any research and development activities on their own account.



Credit risk

ADC Norway AS operated solely in Norway, a country characterized by a very stable macroeconomic environment, therefore the management considers the market risk to be minimal. 90% of the sales in 2024/2025 were generated by three top customers, with whom the company has had a long-lasting business relationship. All three main customers are large entities with European footprint and proved an impeccable payment behaviour throughout the time. Furthermore, ADC Norway AS does closely monitor the credit management. Based on this assessment, the management consider that the credit risk is properly addressed and minimized.

Market

Blood Glucose Monitoring (BGM) market where ADC Norway AS operates, is impacted by technological changes (i.e. CGM). The growth and in-market performance of ADC Norway during the period has compensated for the market decline cause by this technology shift. ADC BGM products can be accessed by patients in all the main pharmacy chains in Norway. Health care professionals and institutional users can access ADC products through wholesalers and hospitals which ensures our presence in all segments of the market.

ADC Norway AS is operating in a therapeutic area of chronic ill patients selling products solutions that is reimbursed at a fixed price by the National health care fund (HELFO). As such, the risk that follows the market development is predictable and manageable.

A going concern

The financial statements are presented under the assumption of going concern and the Board of Directors and the managing director confirm the appropriateness of this assumption. The company has focus on measures to meet new challenges in the market. The statements on the expected development represent the current expectations, estimates and budget plans, which are based on assumptions and naturally contain uncertainties. The actual development can therefore deviate from the expectations presented. The board stresses the uncertainty related to going concern considerations.



Working environment

The number of Head Count in 2024/2025 was 13. The leave of absence due to sickness was 5%. In this accounting period, there has not been registered any damages or accident for employees or tangible assets.

The work environment is considered to be good. The cooperation between the employees has been constructive and contributed positively to the enhancement of working environment and operation.

ADC Norway AS has two men and one woman in the board.

The Board of Director's ambition is, in the long term, to fulfil society's long term expectation regarding equality between the genders.

There has been no incurrence for the board/CEO in case of possible responsibility on behalf of the company.

The external environment

The business operations do only to a small extent directly affect the external environment, considering that ADC Norway AS to a large extent only is commissioning sales for other ADC companies.

Global politics and macroeconomic factors have little impact on the consumption of our BGM products in Norway. Chronically ill patients are still dependent on the products we sell to manage and control their disease. In order to ensure that Norwegian patients with diabetes can still get hold of the medical equipment they are highly dependent on HELFO has increased the reimbursement price of BGM products. This is to ensure that small and medium sized importers and distributors are compensated for the increased capital, raw material and transportations costs following the pandemic situation.

Directors & Officers Liability Insurance

PHC Holdings (PHCHD) and its all subsidiaries (Except for ADC Russia and Amelieff Corporation) is covered under a PHC Group global master Directors & Officers Liability (D&O) program placed and administered in Japan.

Generally, D&O Liability policies cover directors and officers for alleged wrongful acts committed in their capacity as directors and officers subject to policy conditions and exclusions.



Covered loss includes damages, settlements and judgments, and defence costs. Loss does not include fines and penalties. Coverage is generally limited to loss from claims first made against an insured during the policy period.

Board of Ascensia Diabetes Care Norway AS

30th September 2025

Torstein Myhre
Board member, General manager

Maria Josefina Schybergson
Board member

Torkild Sagberg Andersen
Chairman of the Board



Ascensia Diabetes Care Norway AS

Annual report 2024/2025

Board of directors' report

Annual accounts

- Income statement**
- Balance sheet**
- Cash flow statement**
- Notes**

Auditor's report



Ascensia Diabetes Care Norway AS

Income statement 01.04-31.03

NOK	Note	2024/2025	2023/2024
Revenue			
Sales revenue	2, 3	<u>116 198 809</u>	<u>110 706 479</u>
Operating expenses			
Cost of goods sold	3	58 646 928	61 436 340
Payroll expenses	4, 5	29 910 509	24 190 277
Depreciation and amortization	8	51 780	51 779
Other operating expenses	3, 4	<u>19 246 923</u>	<u>18 357 051</u>
Total operating expenses		<u>107 856 139</u>	<u>104 035 447</u>
Operating result		<u>8 342 670</u>	<u>6 671 032</u>
Financial income and expenses			
Other financial income	6	42 155	72 237
Other financial expenses	6	<u>22 046</u>	<u>45 365</u>
Net financial items		<u>20 109</u>	<u>26 872</u>
Result before tax		<u>8 362 779</u>	<u>6 697 904</u>
Tax expense	7	<u>1 841 847</u>	<u>1 474 032</u>
Net profit for the year		<u>6 520 932</u>	<u>5 223 872</u>
Allocated as follows			
Proposed dividends	11	8 326 429	0
Transferred to other equity	11	<u>-1 805 497</u>	<u>5 223 872</u>
Total allocations		<u>6 520 932</u>	<u>5 223 872</u>



Ascensia Diabetes Care Norway AS

Balance sheet as of March 31st

NOK	Note	2024/2025	2023/2024
Fixed assets			
<i>Intangible assets</i>			
Deferred tax asset	7	1 184 627	534 595
Customer base		0	0
Total intangible assets		<u>1 184 627</u>	<u>534 595</u>
<i>Tangible assets</i>			
Fixtures and fittings, tools, office machinery etc.	8	<u>64 724</u>	<u>116 504</u>
Total tangible assets		<u>64 724</u>	<u>116 504</u>
<i>Financial assets</i>			
Other long-term receivables	5	<u>0</u>	<u>224 482</u>
Total financial assets		<u>0</u>	<u>224 482</u>
Total fixed assets		<u>1 249 351</u>	<u>875 581</u>
Current assets			
<i>Receivables</i>			
Accounts receivable	9	23 286 133	19 555 091
Other receivables		<u>800 257</u>	<u>4 178 185</u>
Total receivables		<u>24 086 390</u>	<u>23 733 275</u>
Cash and cash equivalents	10	<u>30 061 482</u>	<u>27 087 641</u>
Total current assets		<u>54 147 872</u>	<u>50 820 917</u>
Total assets		<u>55 397 223</u>	<u>51 696 498</u>




Ascensia Diabetes Care Norway AS


Balance sheet as of March 31st

NOK	Note	2024/2025	2023/2024
Equity			
<i>Paid-in capital</i>			
Share capital	11, 12	103 200	103 200
Share premium	11	14 146 330	14 146 330
Total paid-in capital		14 249 530	14 249 530
<i>Retained earnings</i>			
Other equity	11	0	5 083 471
Total retained earnings		0	5 083 471
Total equity		14 249 530	19 333 000
Liabilities			
<i>Provisions</i>			
Pension liabilities	5	3 232 622	0
Total provisions		3 232 622	0
<i>Other long-term liabilities</i>			
Other long-term liabilities		1 166 674	634 208
Total other long term liabilities		1 166 674	634 208
<i>Current liabilities</i>			
Accounts payable	9	11 644 062	15 502 917
Tax payable	7	2 308 202	1 488 450
Public duties payable	10	5 492 790	7 216 606
Dividends	9, 11	8 326 429	0
Other short-term liabilities		8 976 913	7 521 318
Total current liabilities		36 748 396	31 729 291
Total liabilities		41 147 692	32 363 498
Total equity and liabilities		55 397 223	51 696 498


31 March 2025
Lysaker, 30 September 2025


Electronically signed by: Torstein Myhre
Reason: Approver
Date: Sep 30, 2025 15:00:43 GMT+2

Torstein Myhre
Board member, General manager


Electronically signed by: Maria Schybergson
Reason: Approver
Date: Sep 30, 2025 16:02:04 GMT+2

Maria Josefina Schybergson
Board member


Electronically signed by: Torkild Andersen
Reason: Approver
Date: Sep 30, 2025 15:29:02 GMT+2

Torkild Sagberg Andersen
Chairman of the board



Ascensia Diabetes Care Norway AS

Cash flow statement 01.04-31.03

NOK	Note	2024/2025	2023/2024
Cash flow from operating activities			
Result before tax		8 362 779	6 697 904
Taxes paid		-747 570	101 786
Depreciation and amortisation	8	51 780	51 779
Changes in pension scheme assets/liabilities	5	-745 425	-1 163 929
Changes in accounts receivables and accounts payables		-7 057 430	-2 770 118
Changes in other current balance sheet items		3 109 708	926 639
Net cash flow from operating activities		<u>2 973 842</u>	<u>3 844 061</u>
Cash flow from investing activities			
Net cash flow from investing activities		<u>0</u>	<u>0</u>
Cash flow from financing activities			
Dividends	11	<u>0</u>	<u>-16 800 000</u>
Net cash flow from financing activities		<u>0</u>	<u>-16 800 000</u>
Net change in cash and cash equivalents		2 973 842	-12 955 939
Cash and cash equivalents as of 01.04.2024		<u>27 087 641</u>	<u>40 043 580</u>
Cash and cash equivalents as of 31.03.2025		<u>30 061 483</u>	<u>27 087 641</u>



Ascensia Diabetes Care Norway AS

Notes to the accounts for 2024/2025

NOK

Note - 1 Accounting Principles

The annual report is prepared according to the Norwegian Accounting Act 1998 (with subsequent changes) and generally accepted. The numbers in financial statement are stated in NOK.

Sales revenue

Sales revenues are recognized at the time of delivery. Revenue from services are recognized at execution. The share of sales revenue associated with future services are recorded in the balance sheet as deferred sales revenue, and are recognized at the time of execution.

Ascensia Diabetes Care Norway AS is a wholly owned indirect subsidiary of PHC Holdings Corporation, within the Ascensia Diabetes Care Group. The Company's trading model remains predominantly acting as a sales and marketing entity for the Ascensia Group in Norway, buying finished good product from the Company's parent company, Ascensia Diabetes Care Holdings AG, for resale into Norway.

Balance sheet classification

Net current assets comprise creditors due within one year, and entries related to goods circulation. Other entries are classified as fixed assets and/or long-term creditors.

Current assets are valued at the lower of acquisition cost and fair value. Short-term creditors are recognized at nominal value.

Fixed assets are valued by the cost of acquisition, in the case of non incidental reduction in value the asset will be written down to the fair value amount. Long-term creditors are recognized at nominal value.

Accounts receivable and other receivables

Accounts receivable and other current receivables are recorded in the balance sheet at nominal value less provisions for doubtful debts. Provisions for doubtful debts are calculated on the basis of individual assessments. In addition, for the remainder of accounts receivables outstanding balances, a general provision is carried out based on expected loss.

Foreign currency translation

Foreign currency transactions are translated using the year end exchange rates.

Property, plant and equipment

Property, plant and equipment is capitalized and depreciated over the estimated useful economic life. Direct maintenance costs are expensed as incurred, whereas improvements and upgrading are assigned to the acquisition cost and depreciated along with the asset. If carrying value of a non current asset exceeds the estimated recoverable amount, the asset is written down to the recoverable amount. The recoverable amount is the greater of the net selling price and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value.



Ascensia Diabetes Care Norway AS

Notes to the accounts for 2024/2025

NOK

Pensions

The company pension schemes include a defined benefit plan and a contribution plan. Pension costs and pension liabilities are estimated on the basis of linear earnings and future salary. The calculation is based on assumptions of discount rate, future wage adjustments, pension and other payments from the national insurance fund, future return on pension funds and actuarial assumptions for deaths, voluntary resignation etc. Pension funds are valued at fair value and deducted from net pension liabilities in the balance sheet. The defined benefit obligation is recognized in accordance with IAS 19. Changes in the pension obligations due to changes in pension plans are booked to equity.

Income tax

Tax expenses in the profit and loss account comprise both tax payable for the accounting period and changes in deferred tax. Deferred tax is calculated at 22 percent on the basis of existing temporary differences between accounting profit and taxable profit together with tax deductible deficits at the year end. Temporary differences, both positive and negative, are balanced out within the same period. Deferred tax assets are recorded in the balance sheet to the extent it is more likely than not that the tax assets will be utilized.

Cash flow statement

The cash flow statement is presented using the indirect method. Cash and cash equivalents includes cash, bank deposits and other short-term highly liquid placement with original maturities of three months or less.



Ascensia Diabetes Care Norway AS

Notes to the accounts for 2024/2025

NOK

Note 2 - Sales revenue

	2024/2025	2023/2024
<i>By business area</i>		
Operating in BGM (Blood Glucose Monitoring) marked	116 198 809	110 706 479
<i>Geographical distribution</i>		
Norway	116 198 809	110 706 479

Note 3 - Intercompany transactions with group and associated companies

<i>Sales revenue</i>	2024/2025	2023/2024
ICO service (recharges ADC Norway to ADC Holding)	20 831 426	14 407 057

ADC Holdings is a principle entity that is responsible for global strategy, R&D, packaging and global brand development and marketing. Under the management and control of ADC Holdings, ADC Norway assists ADC Holdings in the execution of its responsibilities by providing the marketing services and management support for the Nordics region.

<i>Cost</i>	2024/2025	2023/2024
ICO services (recharges ADC Holding to ADC Norway)	477 449	483 689
Inventory (COGS)	58 646 928	61 436 340
Total cost	<u>59 124 377</u>	<u>61 920 029</u>

In 2024, ADC Norway reimbursed ADC Holdings for the following third-party costs, initially incurred by ADC Holdings for the benefit of ADC Norway: payroll administration service, travel and expense claims support, IT software and services provided by various vendors, Call centre services, laptops sold by various vendors.



Ascensia Diabetes Care Norway AS

Notes to the accounts for 2024/2025

NOK

Note 4 - Payroll expenses, number of employees and loans to employees and auditor's fee

<i>Payroll expenses</i>	2024/2025	2023/2024
Salaries	20 505 127	17 833 874
Payroll tax	4 049 794	3 429 569
Pension costs	4 238 384	1 211 217
Other payroll expense	1 117 204	1 715 616
Total payroll expenses	<u>29 910 509</u>	<u>24 190 276</u>

Average number of full-time equivalents 13 12

The entity is required to have an occupational pension scheme in accordance with the Act on Mandatory Occupational Pensions. The entity's pension schemes satisfy the requirements of this Act.

Management remuneration to Board

Any remuneration has not paid to the general manager or the board of directors for acting as a member of board during the year. There are no loans/securities issued to the general manager or board of directors.

<i>Auditor fee has been divided as follows</i>	2024/2025
Statutory audit fee	406 599

VAT is not included in the auditor fees.



Ascensia Diabetes Care Norway AS

Notes to the accounts for 2024/2025

NOK

Note 5 - Pensions

The company is obliged to follow "lov om obligatorisk tjenstepensjon" and confirm that the existing pension plan is in compliance with the legislation.

Benefit plan:

The company has a defined benefit pension plan with four participants. The scheme gives entitlement to defined future benefits. These are mainly dependent on the amount of contribution years, salary level at retirement age and the size of benefit from the National Insurance Scheme. The obligations are covered through an insurance company.

	2024/2025	2023/2024
Pension obligation	-21 068 898	-15 757 916
Pension plan assets (market value)	18 556 599	16 599 422
Unfunded defined benefit obligation	<u>-720 323</u>	<u>-617 024</u>
Pension obligation benefit plan	-3 232 622	224 482
Net pension (asset)/liability in the balance sheet	3 232 622	-224 482

Net pension cost booked in P&L is NOK 4 238 384, where NOK 5 034 445 is related to defined contribution plan and NOK -796 061 is related to defined benefit plan. Pension booked against equity is NOK 4 202 529

<i>Principal assumptions:</i>	2024/2025	2023/2024
Discount rate	3,90%	4,00%
Expected compensation increase	4,00%	2,75%
Increases in Social Security	2,50%	1,75%

The actuarial assumptions are based on assumptions of demographic factors normally used within the insurance industry.

Note 6 - Financial income and expense

	2024/2025	2023/2024
<i>Other financial income</i>		
Currency exchange gain	1 123	3 216
Other interest income	<u>41 032</u>	<u>69 021</u>
Total financial income	<u>42 155</u>	<u>72 237</u>
<i>Other financial expenses</i>		
Currency exchange loss	13 174	13 911
Other interest expense	<u>8 872</u>	<u>31 454</u>
Total financial expenses	<u>22 046</u>	<u>45 365</u>



Ascensia Diabetes Care Norway AS

Notes to the accounts for 2024/2025

NOK

Note 7 - Income taxes

<i>Income tax expense</i>	2024/2025	2023/2024
Tax payable	1 567 322	1 036 762
Change in deferred tax	274 525	437 270
Total income tax expense	<u>1 841 847</u>	<u>1 474 032</u>
<i>Tax base estimation</i>	2024/2025	2023/2024
Result before tax	8 362 779	6 697 904
Permanent differences	9 252	2 242
Change in temporary differences	2 954 691	-826 450
Of which pension booked to Equity	-4 202 529	-1 161 140
Tax base	<u>7 124 193</u>	<u>4 712 556</u>
Tax payable (22%) of the tax base	1 567 322	1 036 762
Tax payable from prior years	740 880	451 688
Tax payable in balance sheet	<u>2 308 202</u>	<u>1 488 450</u>
<i>Temporary differences outlined</i>	2024/2025	2023/2024
Fixed assets	-2 152 047	-2 654 459
Pension (assets)/ liabilities	-3 232 622	224 482
Net temporary differences	<u>-5 384 669</u>	<u>-2 429 977</u>
Deferred income tax (-asset) (22%)	-1 184 627	-534 595
<i>Effective tax rate</i>	2024/2025	
Expected income taxes, statutory tax rate 22%	1 839 811	
Tax cost booked to OCI	924 556	
Permanent differences (22%)	-922 520	
Income tax expense	<u>1 841 847</u>	
Effective tax rate*)	22 %	

*) Tax expense divided by pre-tax income



Ascensia Diabetes Care Norway AS

Notes to the accounts for 2024/2025

NOK

Note 8 - Tangible assets

	Furniture and fixtures, tools etc	Total
Acquisition cost 01.04.	517 795	517 795
Acquisition cost 31.03.	517 795	517 795
Acc.depreciation 31.03.	-453 071	-453 071
Net carrying amount as of 31.03.	64 724	64 724
Depreciation for the year	51 780	51 780
Useful economic life Depreciation Plan	10 years Linear	

Note 9 - Intercompany balances with group and associated companies

Receivables	2024/2025	2023/2024
Accounts receivable	10 850 636	107 774
Payables	2024/2025	2023/2024
Accounts payable	10 277 348	13 015 667
Dividend	8 326 429	0
Total intercompany payables	18 603 777	13 015 667

Note 10 - Bank deposit

	2024/2025
Restricted cash for employee withholding taxes as of 31.03.	565 119

Note 11 - Equity

	Share capital	Share premium	Other equity	Total
Equity 01.04.	103 200	14 146 330	5 083 470	19 333 000
Net profit for the year	0	0	6 520 932	6 520 932
Pension	0	0	-3 277 973	-3 277 973
Dividend	0	0	-8 326 429	-8 326 429
Equity 31.03.	103 200	14 146 330	0	14 249 530



Ascensia Diabetes Care Norway AS

Notes to the accounts for 2024/2025

NOK

Note 12 - Share capital and shareholder information

Share capital:

	Number of shares	Face value, NOK	Book value, NOK
Ordinary shares	2 400	43	103 200

Shareholders per 31.03:

	Ordinary shares	Ownership share	Voting rights
Ascensia Diabetes Care Holdings AG	2 400	100 %	100 %

The entity is part of the consolidated accounts for Ascensia Diabetes Care Holdings AG, whose address is:
Ascensia Diabetes Care Holdings AG, Merian-Str. 90, 4052 Basel, Switzerland.

The consolidated accounts can be obtained from:

<https://holdings.panasonic/global/corporate/investors.html>



Ascensia Diabetes Care Norway AS Final FS

Final Audit Report

2025-09-30

Created:	2025-09-30
By:	Anita Albertin-Renczés (anita.renczes@ascensia.com)
Status:	Signed
Transaction ID:	CBJCHBCAABAAIH17hnqTK7v1MA1NWnK6yTA7euA0N2-0

"Ascensia Diabetes Care Norway AS Final FS" History


- Document created by Anita Albertin-Renczés (anita.renczes@ascensia.com)
2025-09-30 - 12:36:30 PM GMT
- Document emailed to Torstein Myhre (torstein.myhre@ascensia.com) for signature
2025-09-30 - 12:37:36 PM GMT
- Email viewed by Torstein Myhre (torstein.myhre@ascensia.com)
2025-09-30 - 12:57:29 PM GMT
- Torstein Myhre (torstein.myhre@ascensia.com) authenticated with Adobe Acrobat Sign.
Challenge: The user completed the signing ceremony.
2025-09-30 - 1:00:41 PM GMT
- Document e-signed by Torstein Myhre (torstein.myhre@ascensia.com)
Signing reason: Approver
Signature Date: 2025-09-30 - 1:00:43 PM GMT - Time Source: server
- Document emailed to Torkild Andersen (torkild.andersen@ascensia.com) for signature
2025-09-30 - 1:00:44 PM GMT
- Anita Albertin-Renczés (anita.renczes@ascensia.com) added alternate signer gctoa@ascensia.net. The original signer Torkild Andersen (torkild.andersen@ascensia.com) can still sign.
2025-09-30 - 1:26:06 PM GMT
- Document emailed to gctoa@ascensia.net for signature
2025-09-30 - 1:26:07 PM GMT
- Torkild Andersen (torkild.andersen@ascensia.com) authenticated with Adobe Acrobat Sign.
Challenge: The user completed the signing ceremony.
2025-09-30 - 1:29:01 PM GMT
- Document e-signed by Torkild Andersen (torkild.andersen@ascensia.com)
Signing reason: Approver





Powered by
Adobe
Acrobat Sign




Signature Date: 2025-09-30 - 1:29:02 PM GMT - Time Source: server


 Document emailed to Maria Schybergson (maria.schybergson@ascensia.com) for signature
2025-09-30 - 1:29:05 PM GMT

 Anita Albertin-Renczés (anita.renczes@ascensia.com) added alternate signer nomsc@ascensia.net. The original signer Maria Schybergson (maria.schybergson@ascensia.com) can still sign.
2025-09-30 - 2:00:47 PM GMT

 Document emailed to nomsc@ascensia.net for signature
2025-09-30 - 2:00:47 PM GMT

 Maria Schybergson (maria.schybergson@ascensia.com) authenticated with Adobe Acrobat Sign.
Challenge: The user completed the signing ceremony.
2025-09-30 - 2:02:02 PM GMT

 Document e-signed by Maria Schybergson (maria.schybergson@ascensia.com)
Signing reason: Approver
Signature Date: 2025-09-30 - 2:02:04 PM GMT - Time Source: server

 Agreement completed.
2025-09-30 - 2:02:04 PM GMT